November 30, 2016 - By Clifton Ray · 0 Comments
The stock of Corium International Incorporated (NASDAQ:CORI) registered an increase of 1.21% in short interest. CORI’s total short interest was 569,500 shares in November as published by FINRA. Its up 1.21% from 562,700 shares, reported previously. With 25,600 shares average volume, it will take short sellers 22 days to cover their CORI’s short positions. The short interest to Corium International Incorporated’s float is 6.17%. The stock increased 0.18% or $0.01 on November 29, hitting $5.44. Corium International Inc (NASDAQ:CORI) has risen 28.00% since April 27, 2016 and is uptrending. It has outperformed by 22.77% the S&P500.
Corium International, Inc. is a biopharmaceutical company. The company has a market cap of $120.04 million. The Firm is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. It currently has negative earnings. The Company’s development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.
Insitutional Activity: The institutional sentiment decreased to 0.69 in 2016 Q2. Its down 0.04, from 0.73 in 2016Q1. The ratio fall, as 12 funds sold all Corium International Inc shares owned while 14 reduced positions. 8 funds bought stakes while 11 increased positions. They now own 18.39 million shares or 2.90% less from 18.94 million shares in 2016Q1.
Morgan Stanley holds 2,614 shares or 0% of its portfolio. Globeflex L P accumulated 0% or 102 shares. Tfs Capital Limited Liability Company has invested 0.02% of its portfolio in Corium International Inc (NASDAQ:CORI). Blackrock Fund Advsr reported 35,108 shares or 0% of all its holdings. Blackrock Institutional Trust Company Na has 66,313 shares for 0% of their US portfolio. Moreover, Paloma Ptnrs Management has 0% invested in Corium International Inc (NASDAQ:CORI) for 43,789 shares. Opaleye Management accumulated 1.4% or 125,000 shares. Citigroup accumulated 2,000 shares or 0% of the stock. Barclays Pcl last reported 981 shares in the company. State Bank Of America De last reported 0% of its portfolio in the stock. Tci Wealth Advsr Incorporated accumulated 162 shares or 0% of the stock. Wall Street holds 265,700 shares or 0.37% of its portfolio. Rtw Investments Limited Liability Company has 852,961 shares for 1.01% of their US portfolio. Essex Woodlands Health Ventures has 8.18% invested in the company for 9.35M shares. Bancorporation Of New York Mellon owns 14,432 shares or 0% of their US portfolio.
Out of 5 analysts covering Corium International (NASDAQ:CORI), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Corium International has been the topic of 9 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Needham on Tuesday, February 9. On Monday, August 31 the stock rating was downgraded by WBB Securities to “Hold”. The company was downgraded on Tuesday, August 25 by Zacks. The stock has “Buy” rating given by Zacks on Wednesday, September 2. The rating was maintained by Needham with “Buy” on Monday, November 16.
Corium International, Inc., incorporated on February 28, 2002, is a biopharmaceutical company. The Firm is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. The Company’s development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules that are difficult to deliver in a transdermal dosage form. The Company’s Corplex and MicroCor platforms address some of the primary shortcomings of traditional transdermal drug delivery.
Another recent and important Corium International Inc (NASDAQ:CORI) news was published by Quotes.Wsj.com which published an article titled: “News Corium International Inc.CORI” on April 16, 2011.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Clifton Ray